RayThera
RayThera is a preclinical biotechnology company developing small molecule drug candidates targeting anti-inflammatory pathways for immune-mediated diseases. Founded in 2023 in San Diego, it is advancing three preclinical assets toward Phase 1 under a pending Biogen acquisition.
- Company typePrivate
- Founded2023
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RayThera does
RayThera is a privately held, preclinical-stage biotechnology company founded in August 2023 and headquartered at 11988 El Camino Real, Suite 600, San Diego, California. The company is developing small molecule drug candidates that target anti-inflammatory pathways to address unmet medical needs in immunology and immune-mediated conditions. RayThera operates with a small team (1-10 employees) and is advancing a pipeline of three preclinical anti-inflammatory assets, with the lead candidate expected to enter Phase 1 clinical development in early Q3 2026. Indications remain undisclosed.
RayThera firmographics
Firmographics- Name
- RayThera
- Legal name
- RayThera Inc.
- Website
- https://raythera.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RayThera is a preclinical biotechnology company developing small molecule drug candidates targeting anti-inflammatory pathways for immune-mediated diseases. Founded in 2023 in San Diego, it is advancing three preclinical assets toward Phase 1 under a pending Biogen acquisition.
- Ownership category
- akta.pro rank
RayThera industry classification
Industry- Product category
- Preclinical Immunology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
Keywords
Where RayThera is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RayThera business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Drug Development and Commercialization: Pre-revenue biotech company developing small molecule drug candidates for immunological diseases. Revenue would be generated through eventual pharmaceutical product sales following successful clinical development and regulatory approval, or through acquisition by larger pharmaceutical companies.
Marketing channels1 record
RayThera product offering
Product offeringCore offering
RayThera is a preclinical biotechnology company developing small molecule drug candidates targeting anti-inflammatory pathways for immune-mediated conditions. The company operates a pipeline of three preclinical anti-inflammatory assets, with its lead candidate advancing toward Phase 1 clinical development. Founded in 2023 and headquartered in San Diego, RayThera focuses exclusively on small molecule therapies for unmet needs in immunology.
Product overview
RayThera is a small molecule drug discovery company developing a pipeline of anti-inflammatory drug candidates for immunological diseases. Founded in August 2023, the company operates a preclinical pipeline with multiple anti-inflammatory assets that were being advanced toward clinical trials. The company's research platform focuses on small molecule therapies targeting immune-mediated conditions, with the lead candidate expected to enter Phase 1 development in early Q3 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Anti-Inflammatory Drug Pipeline Pipeline of three preclinical small molecule drug candidates targeting anti-inflammatory pathways for immune-mediated conditions, with the lead candidate advancing toward Phase 1 clinical development. Targeted at pharmaceutical partners and acquirers developing therapeutics for immunological diseases with unmet medical need.
Companies that use RayThera
Customer profileSegments1 record
Ideal customer profiles2 records
RayThera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
RayThera partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights4 records
RayThera competitors and assessment
Company assessmentDirect peers
- XinThera: The same co-founders' immediately prior venture, which they built around small molecule discovery in immunology/inflammation and sold to Gilead for $200M in May 2023. Highly comparable as a near-identical playbook executed just before RayThera.
Emerging players
- Alumis: Clinical-stage immunology biotech that acquired FronThera (the founders' earlier company) in February 2021. Comparable as a small-molecule immunology company with similar scientific lineage and target-area focus.
- Dice Therapeutics: Small molecule immunology biotech (acquired by Eli Lilly for ~$2.4B in 2023) developing oral IL-17 inhibitors for autoimmune diseases — a directly analogous 'oral small molecule in immunology' thesis to RayThera's pipeline.
- Prometheus Biosciences: Immunology-focused biotech acquired by Merck for ~$10.8B in 2023. Comparable as a later-stage immunology platform that demonstrated the premium pharma is willing to pay for differentiated immunology assets.
- Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders with a strong focus on immunology indications. Comparable as a small-molecule immunology platform that has progressed to public markets and clinical validation.
- Nimbus Therapeutics: Private small molecule drug discovery platform that has produced several partnered assets with major pharma. Comparable as a structure-based design-driven small molecule discovery company.
- Frontier Medicines: Small molecule precision medicine company focused on previously undruggable targets, with programs in oncology and immunology. Comparable as a privately-funded small molecule discovery platform pursuing challenging targets.
- EQRx: Small molecule drug development company focused on innovative therapies in oncology and immunology at lower cost. Comparable as a small-molecule platform with a thesis of producing better-access innovative drugs.
- Edgewise Therapeutics: Clinical-stage small muscle biology company with selective small molecule approaches. Comparable as a small-molecule drug discovery company that has progressed through venture funding toward clinical development.
Broad incumbents
- Rigel Pharmaceuticals: Commercial-stage small molecule company with a focus on immunology/hematology (e.g., Tavalisse, Rezlidhia). Comparable as a small-molecule player focused on immune-mediated diseases, though at a much more mature commercial stage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights7 records
Customer concentration
RayThera financial estimates
Financial estimateRevenue estimate
Valuation estimate
RayThera leadership team
Management profileNumber of profiles
Profiles9 records
RayThera funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RayThera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RayThera
What does RayThera do?
RayThera is a preclinical biotechnology company developing small molecule drug candidates targeting anti-inflammatory pathways for immune-mediated conditions. The company operates a pipeline of three preclinical anti-inflammatory assets, with its lead candidate advancing toward Phase 1 clinical development. Founded in 2023 and headquartered in San Diego, RayThera focuses exclusively on small molecule therapies for unmet needs in immunology.
Is RayThera a public or private company?
RayThera is a private company. It is classified as venture growth investor backed and is currently operating.
When was RayThera founded?
RayThera was founded in 2023. It employs 1 to 10 people.
Where is RayThera based?
RayThera is headquartered in San Diego, United States, in the North America region.
How does RayThera make money?
One revenue line is on record: drug Development and Commercialization.
Who are RayThera's main competitors?
XinThera is listed as a direct peer. Emerging players are Alumis, Dice Therapeutics, Prometheus Biosciences, Kymera Therapeutics, Nimbus Therapeutics, Frontier Medicines, EQRx and Edgewise Therapeutics. Rigel Pharmaceuticals is listed as a broad incumbent.
Does RayThera have an API?
No public API is recorded for RayThera.
What industry is RayThera in?
RayThera's product category is Preclinical Immunology Drug Discovery. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 541714.